Variant has entered a multi-year research partnership with Novo Nordisk to identify new targets to treat metabolic conditions.

Evotec and Novo Nordisk launched LAB eN² in September 2023 with four academic institutions, Harvard University, Mass General Brigham, Yale School of Medicine, and Beth Israel Deaconess Medical ...

The issuer is solely responsible for the content of this announcement. Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General ...

Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture ...

(RTTNews) - Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center for development ...

First three selected projects will focus on research for different cardiometabolic conditions.

Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk 11.12.2024 / 07:29 CET/CEST The issuer is solely responsible for the content of this announcement.

"We are thrilled to be able to start work on these first projects, leveraging Evotec's integrated drug discovery and translational platforms and Novo Nordisk's deep disease understanding," said ...

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² ...

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three projects and launched an expansion featuring five new academic partners.

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² ...